PH20016A - Cardioselective aryloxy-and arylthio-hydroxy-propylene piperazinyl acetamides which affect calcium entry - Google Patents

Cardioselective aryloxy-and arylthio-hydroxy-propylene piperazinyl acetamides which affect calcium entry

Info

Publication number: PH20016A
Authority: PH; Philippines
Prior art keywords: lower alkyl; cardioselective; independently hydrogen; together form; calcium entry
Prior art date: 1983-05-18

Application number

PH30692A

Other languages

English (en)

Inventor

Arthur F Kluge

Robin D Clark

Arthur M Strosberg

Jean Claude Pascal

Roger L Whiting

Original Assignee

Syntex Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-05-18

Filing date

1984-05-17

Publication date

1986-09-01

1984-05-17 Application filed by Syntex Inc filed Critical Syntex Inc

1986-09-01 Publication of PH20016A publication Critical patent/PH20016A/en

Links

230000003185 calcium uptake Effects 0.000 title abstract 2
125000000217 alkyl group Chemical group 0.000 abstract 3
229910052739 hydrogen Inorganic materials 0.000 abstract 3
239000001257 hydrogen Substances 0.000 abstract 3
125000003545 alkoxy group Chemical group 0.000 abstract 2
125000004644 alkyl sulfinyl group Chemical group 0.000 abstract 2
125000004390 alkyl sulfonyl group Chemical group 0.000 abstract 2
125000004414 alkyl thio group Chemical group 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
125000004093 cyano group Chemical group *C#N 0.000 abstract 2
125000001475 halogen functional group Chemical group 0.000 abstract 2
150000002431 hydrogen Chemical group 0.000 abstract 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
206010002383 Angina Pectoris Diseases 0.000 abstract 1
208000024172 Cardiovascular disease Diseases 0.000 abstract 1
201000001068 Prinzmetal angina Diseases 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
239000002253 acid Substances 0.000 abstract 1
125000002252 acyl group Chemical group 0.000 abstract 1
125000003282 alkyl amino group Chemical group 0.000 abstract 1
-1 aminocarbonylmethyl Chemical group 0.000 abstract 1
206010003119 arrhythmia Diseases 0.000 abstract 1
230000006793 arrhythmia Effects 0.000 abstract 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
150000002148 esters Chemical class 0.000 abstract 1
125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
229910052760 oxygen Inorganic materials 0.000 abstract 1
239000001301 oxygen Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
229910052717 sulfur Chemical group 0.000 abstract 1
239000011593 sulfur Chemical group 0.000 abstract 1
238000002560 therapeutic procedure Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D303/00—Compounds containing three-membered rings having one oxygen atom as the only ring hetero atom
- C07D303/02—Compounds containing oxirane rings
- C07D303/12—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms
- C07D303/18—Compounds containing oxirane rings with hydrocarbon radicals, substituted by singly or doubly bound oxygen atoms by etherified hydroxyl radicals
- C07D303/20—Ethers with hydroxy compounds containing no oxirane rings
- C07D303/22—Ethers with hydroxy compounds containing no oxirane rings with monohydroxy compounds
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/66—Nitrogen atoms not forming part of a nitro radical

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Hydrogenated Pyridines (AREA)
Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
Pyridine Compounds (AREA)
Cosmetics (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Polyesters Or Polycarbonates (AREA)
Medicinal Preparation (AREA)

PH30692A 1983-05-18 1984-05-17 Cardioselective aryloxy-and arylthio-hydroxy-propylene piperazinyl acetamides which affect calcium entry PH20016A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US06/495,904 US4567264A (en)	1983-05-18	1983-05-18	Cardioselective aryloxy- and arylthio- hydroxypropylene-piperazinyl acetanilides which affect calcium entry

Publications (1)

Publication Number	Publication Date
PH20016A true PH20016A (en)	1986-09-01

Family

ID=23970461

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PH30692A PH20016A (en)	1983-05-18	1984-05-17	Cardioselective aryloxy-and arylthio-hydroxy-propylene piperazinyl acetamides which affect calcium entry

Country Status (26)

Country	Link
US (1)	US4567264A (cs)
EP (1)	EP0126449B1 (cs)
JP (1)	JPS59219271A (cs)
KR (1)	KR890000020B1 (cs)
AT (1)	ATE31533T1 (cs)
AU (1)	AU566489B2 (cs)
BR (1)	BR1100474A (cs)
CA (1)	CA1256874A (cs)
CS (1)	CS246080B2 (cs)
DE (1)	DE3468215D1 (cs)
DK (1)	DK168535B1 (cs)
ES (1)	ES532565A0 (cs)
FI (1)	FI78479C (cs)
HK (1)	HK91989A (cs)
HU (1)	HU192404B (cs)
IE (1)	IE57487B1 (cs)
IL (1)	IL71863A (cs)
MX (1)	MX9203001A (cs)
NO (1)	NO163618C (cs)
NZ (1)	NZ208188A (cs)
PH (1)	PH20016A (cs)
PL (2)	PL142760B1 (cs)
PT (1)	PT78604B (cs)
RU (2)	RU2071471C1 (cs)
SG (1)	SG25086G (cs)
ZA (1)	ZA843746B (cs)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5028610A (en) *	1987-03-18	1991-07-02	Sankyo Company Limited	N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use
WO1990007506A1 (fr) *	1988-12-26	1990-07-12	Kowa Company, Ltd.	Production d'ether de glycidyle
ATE218344T1 (de) *	1989-06-23	2002-06-15	Syntex Llc	Ranolazin und verwandte piperazine zur behandlung von schockzuständen
HU209723B (en) *	1990-10-31	1994-10-28	Richter Gedeon Vegyeszet	Process for producing of piperazine derivatives
US5455045A (en) *	1993-05-13	1995-10-03	Syntex (U.S.A.) Inc.	High dose formulations
EP0775128A1 (en) *	1995-06-07	1997-05-28	Dade Chemistry Systems Inc.	Preparation of immunogens and other conjugates of drugs
TWI245035B (en) *	1998-06-26	2005-12-11	Ono Pharmaceutical Co	Amino acid derivatives and a pharmaceutical composition comprising the derivatives
US6479496B1 (en) *	1998-09-10	2002-11-12	Cv Therapeutics, Inc.	Methods for treating angina with ranolazine
US6303607B1 (en)	1998-09-10	2001-10-16	Cv Therapeutics, Inc.	Method for administering a sustained release ranolanolazine formulation
HK1048250A1 (zh)	2000-02-18	2003-03-28	Cv Therapeutics, Inc.	在治疗充血性心力衰竭中使用的部分脂肪酸氧化抑制剂
US6451798B2 (en) *	2000-02-22	2002-09-17	Cv Therapeutics, Inc.	Substituted alkyl piperazine derivatives
US6677343B2 (en)	2000-02-22	2004-01-13	Cv Therapeutics, Inc.	Substituted piperazine compounds
US6677336B2 (en) *	2000-02-22	2004-01-13	Cv Therapeutics, Inc.	Substituted piperazine compounds
US6552023B2 (en)	2000-02-22	2003-04-22	Cv Therapeutics, Inc.	Aralkyl substituted piperazine compounds
US6638970B2 (en)	2000-02-22	2003-10-28	Cv Therapeutics, Inc.	Substituted alkylene diamine compounds
CA2657986A1 (en) *	2000-02-22	2001-08-30	Cv Therapeutics, Inc.	Substituted piperazine compounds
WO2002007716A2 (en) *	2000-07-21	2002-01-31	Cv Therapeutics, Inc.	Method for treating angina
US6693099B2 (en) *	2000-10-17	2004-02-17	The Procter & Gamble Company	Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6573264B1 (en)	2000-10-23	2003-06-03	Cv Therapeutics, Inc.	Heteroaryl alkyl piperazine derivatives
DE10123129A1 (de) *	2001-05-02	2002-11-14	Berolina Drug Dev Ab Svedala	Deuterierte 3-Piperidinopropiophenone sowie diese Verbindungen enthaltende Arzneimittel
WO2003008411A1 (en) *	2001-07-19	2003-01-30	Cv Therapeutics, Inc.	Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
US7001909B2 (en) *	2001-07-19	2006-02-21	Cv Therapeutics, Inc.	Substituted heterocyclic compounds
IL163666A0 (en)	2002-02-22	2005-12-18	New River Pharmaceuticals Inc	Active agent delivery systems and methods for protecting and administering active agents
US20080109040A1 (en) *	2002-04-04	2008-05-08	Luiz Belardinelli	Method of treating arrhythmias
US20030220344A1 (en) *	2002-04-04	2003-11-27	Luiz Belardinelli	Method of treating arrhythmias
CA2486712C (en) *	2002-05-21	2012-01-03	Cv Therapeutics, Inc.	Method of treating diabetes
US8822473B2 (en) *	2002-05-21	2014-09-02	Gilead Sciences, Inc.	Method of treating diabetes
JP4846234B2 (ja)	2002-06-24	2011-12-28	ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ	Ｎ−（２，６−ジメチル−フェニル）−２−ピペラジン−１−イル−アセトアミドの製造方法
US7056924B2 (en) *	2002-07-18	2006-06-06	Cv Therapeutics, Inc.	Substituted heterocyclic compounds
JP2006510670A (ja) *	2002-12-05	2006-03-30	シーブイ・セラピューティクス・インコーポレイテッド	置換ヘテロ環化合物
EP1806346B1 (en) *	2002-12-05	2009-07-22	Cv Therapeutics, Inc.	Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
JP2006514066A (ja) *	2003-01-03	2006-04-27	シーブイ・セラピューティクス・インコーポレイテッド	置換ヘテロ環化合物
AU2004209522A1 (en) *	2003-01-17	2004-08-19	Gilead Palo Alto, Inc.	Substituted heterocyclic compounds useful in the treatment of cardiovascular diseases
KR20060065586A (ko) *	2003-06-23	2006-06-14	씨브이 쎄러퓨틱스, 인코포레이티드	지방산 산화 저해제로서의, 피페라진 및 피페리딘의 우레아유도체
WO2005061470A1 (en)	2003-12-18	2005-07-07	Cv Therapeutics, Inc.	1-akan-2-ol substituted piperazine and piperidine compounds
WO2006008753A1 (en) *	2004-07-19	2006-01-26	Unichem Laboratories Limited	Crystalline and amorphous form of ranolazine and the process for manufacturing them
EP1789407A2 (en) *	2004-09-08	2007-05-30	Cv Therapeutics, Inc.	Substituted piperazine compounds and their use as fatty acid oxidation inhibitors
WO2006074398A2 (en) *	2005-01-06	2006-07-13	Cv Therapeutics, Inc.	Sustained release pharmaceutical formulations comprising ranolazine
WO2008047388A2 (en) *	2006-10-20	2008-04-24	Ind-Swift Laboratories Limited	Improved process for the preparation of ranolazine
JP2010518171A (ja) *	2007-02-13	2010-05-27	ギリアード・パロ・アルト・インコーポレイテッド	非冠微小血管疾患の処置のためのラノラジンの使用
US20090111826A1 (en) *	2007-02-13	2009-04-30	Louis Lange	Use of ranolazine for the treatment of cardiovascular diseases
EP2117508A1 (en)	2007-02-13	2009-11-18	CV Therapeutics Inc.	Intravenous solutions comprising ranolazine
US20080248112A1 (en) *	2007-02-13	2008-10-09	Brent Blackburn	Use of ranolazine for the treatment of coronary microvascular diseases
US7943620B2 (en) *	2007-03-07	2011-05-17	Concert Pharmaceuticals, Inc.	Anti-anginal compounds
US20080233191A1 (en) *	2007-03-22	2008-09-25	Brent Blackburn	Use of ranolazine for elevated brain-type natriuretic peptide
WO2008139492A2 (en) *	2007-05-15	2008-11-20	Natco Pharma Limited	A process for the preparation of highly pure ranolazine base
WO2008150565A2 (en) *	2007-05-31	2008-12-11	Cv Therapeutics, Inc.	Ranolazine for elevated brain-type natriuretic peptide
RU2442585C2 (ru) *	2007-05-31	2012-02-20	Си Ви Терапьютикс, Инк.	Способ лечения диабета
CA2690379A1 (en) *	2007-06-13	2008-12-24	Auspex Pharmaceuticals, Inc.	Substituted piperazines
US20090247535A1 (en) *	2008-03-26	2009-10-01	Duke University	Use of ranolazine for non-cardiovascular disorders
AR072196A1 (es) *	2008-06-19	2010-08-11	Medichem Sa	Procedimiento para preparar ranolazina purificada, util en el tratamiento cronico de la angina.
WO2010025370A2 (en) *	2008-08-28	2010-03-04	Dr. Reddy's Laboratories Ltd.	Preparation of ranolazine
WO2010023687A2 (en) *	2008-08-28	2010-03-04	Shodhana Laboratories Limited	Preparation of ranolazine, its salts and intermediates thereof
US20110300218A1 (en) *	2008-09-09	2011-12-08	Actavis Group Ptc Ehf	Novel solid state forms of ranolazine salts
US20110223213A1 (en) *	2008-10-15	2011-09-15	Actavis Group Ptc Ehf	Highly pure ranolazine or a pharmaceutically acceptable salt thereof
WO2010097805A1 (en)	2009-02-24	2010-09-02	Lupin Limited	A process for the preparation of ranolazine
US8901128B2 (en)	2009-05-28	2014-12-02	Lupin Limited	Pharmaceutical compositions of ranolazine
US20120177729A1 (en)	2009-09-25	2012-07-12	Lupin Limited	Sustained release composition of ranolazine
TWI508726B (zh)	2009-12-21	2015-11-21	Gilead Sciences Inc	治療心房纖維性顫動之方法
TW201215392A (en)	2010-06-16	2012-04-16	Gilead Sciences Inc	Use of ranolazine for treating pulmonary hypertension
NO3175985T3 (cs)	2011-07-01	2018-04-28
CA2849505A1 (en)	2011-09-21	2013-03-28	Gilead Sciences, Inc.	Sodium channel blockers reduce glucagon secretion
CN103570645A (zh) *	2012-08-01	2014-02-12	上海迪赛诺化学制药有限公司	一种制备n-(2,6-二甲基苯基)-2-(1-哌嗪基)乙酰胺的方法
EP3782992A1 (en)	2015-03-10	2021-02-24	Unichem Laboratories Limited	Novel process for the preparation of ranolazine
TW201717919A (zh)	2015-07-02	2017-06-01	國際藥品股份公司	雷諾多重壓縮錠劑
WO2018001582A1 (en)	2016-06-30	2018-01-04	Interquim, S.A.	Ranolazine multiple compressed tablets
WO2021252951A1 (en)	2020-06-12	2021-12-16	Vanderbilt University	Methods of treatment for gastrointestinal motility disorders
CN118680891B (zh) *	2024-08-20	2025-01-28	湖州亚瑟制药有限公司	一种用于治疗心绞痛的制剂组合物及其制备方法

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3829441A (en) *	1962-01-29	1974-08-13	Smith Kline French Lab	Guanidinoalkylbenzodioxan derivatives
US3360529A (en) *	1962-01-29	1967-12-26	Smith Kline French Lab	Guanidinoalkylbenzodioxan derivatives
US3496183A (en) *	1964-11-19	1970-02-17	Egyt Gyogyszervegyeszeti Gyar	Beta-guanidino-ethyl-piperazine derivatives
DE1795362A1 (de) *	1968-09-19	1972-01-05	Boehringer Mannheim Gmbh	Basische AEther und Verfahren zur Herstellung derselben
DE1795375A1 (de) *	1968-09-21	1972-01-05	Boehringer Mannheim Gmbh	Basische AEther und Verfahren zur Herstellung derselben
FR2154493B1 (cs) *	1971-09-13	1975-10-31	Kali Chemie Ag
GB1332008A (en) *	1971-09-28	1973-10-03	Pfizer Ltd	Piperazine derivatives their preparation and pharmaceutical compositions containing them
GB1374366A (en) *	1972-07-21	1974-11-20	Science Union & Cie	Propanol derivatives and a process for their preparation
GB1425559A (en) *	1972-09-01	1976-02-18	Wyeth John & Brother Ltd	Pyridine tetrahydropyridine and piperidine derivatives
GB1411531A (en) *	1972-10-24	1975-10-29	Lafon Labor	Amino derivatives of 1,4-benzodioxan
US3953448A (en) *	1972-12-07	1976-04-27	Delmar Chemicals Limited	Piperazino-anilido compounds
FR2267104A1 (en) *	1974-04-12	1975-11-07	Ferlux Labo Sa	Hypotensive and antiarrhythmic piperazines - 1-(3-phenoxy-2-hydroxy propyl)-4-substd. piperazines
FR2310763A1 (fr) *	1975-05-13	1976-12-10	Buzas Andre	Derives 1,4-disubstitues de la piperazine, leur procede de preparation et leurs applications
US4335126A (en) *	1977-03-10	1982-06-15	Degussa Aktiengesellschaft	1-[3-(3,4,5-Trimethoxyphenoxy)-2-hydroxy-propyl]-4-aryl-piperazine-derivatives having pharmaceutical activity
FR2462432A2 (fr) *	1979-08-03	1981-02-13	Delalande Sa	Nouveaux derives de la 3,4,5 trimethoxy cinnamoyle piperazine, leur procede de preparation et leur application en therapeutique
FR2387971A1 (fr) *	1977-04-19	1978-11-17	Delalande Sa	Nouvelles trimethoxy cinnamoyles piperazines, leur procede de preparation et leur application en therapeutique
FR2456738A2 (fr) *	1978-04-10	1980-12-12	Delalande Sa	Nouvelles cinnamoyles piperazines et homopiperazines, leur procede de preparation et leur application en therapeutique
JPS6042795B2 (ja) *	1978-10-23	1985-09-25	日本新薬株式会社	カルバモイルピペラジン誘導体
DE3068678D1 (en) *	1979-08-10	1984-08-30	Sandoz Ag	3-aminopropoxyaryl derivatives, their preparation and pharmaceutical compositions containing them
DE2941597A1 (de) *	1979-10-13	1981-04-23	Basf Ag, 6700 Ludwigshafen	Piperidinderivate von 4,5-dialkyl-3-hydroxy-pyrrol-2-carbonsaeureestern, ihre herstellung und diese enthaltende pharmazeutische zubereitungen
GR71991B (cs) *	1980-01-21	1983-08-26	Delalande Sa
DE3005287A1 (de) *	1980-02-13	1981-08-20	Basf Ag, 6700 Ludwigshafen	Phenylpiperazinderivate von 1,3,4-oxadiazolylphenolen, ihre herstellung und diese enthaltende therapeutische mittel
US4302469A (en) *	1980-09-10	1981-11-24	Syntex (U.S.A.) Inc.	2-(1,4-Benzodioxan-2-ylalkyl)imidazoles useful as antidepressants
US4684651A (en) *	1981-03-17	1987-08-04	Mitsubishi Chemical Industries Limited	Alkylenedioxybenzene and acid addition salts thereof useful as hypotensives
US4766125A (en) *	1981-06-23	1988-08-23	Janssen Pharmaceutica N.V.	N-aryl-piperazinealkanamides useful for protecting hearts from myocardial injury caused by ischaemia, anoxia or hypoxia
US4374837A (en) *	1981-07-31	1983-02-22	Laroche Navarron, S.A.	Piperazine derivatives of theobromine
US4353901A (en) *	1981-10-19	1982-10-12	Syntex (U.S.A.) Inc.	9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones

1983
- 1983-05-18 US US06/495,904 patent/US4567264A/en not_active Expired - Lifetime
1984
- 1984-05-16 NO NO841968A patent/NO163618C/no not_active IP Right Cessation
- 1984-05-17 PT PT78604A patent/PT78604B/pt unknown
- 1984-05-17 HU HU841902A patent/HU192404B/hu unknown
- 1984-05-17 SG SG598/89A patent/SG25086G/en unknown
- 1984-05-17 CS CS843680A patent/CS246080B2/cs unknown
- 1984-05-17 KR KR1019840002696A patent/KR890000020B1/ko not_active Expired
- 1984-05-17 AT AT84105643T patent/ATE31533T1/de not_active IP Right Cessation
- 1984-05-17 PH PH30692A patent/PH20016A/en unknown
- 1984-05-17 NZ NZ208188A patent/NZ208188A/en unknown
- 1984-05-17 PL PL1984247722A patent/PL142760B1/pl unknown
- 1984-05-17 ZA ZA843746A patent/ZA843746B/xx unknown
- 1984-05-17 IL IL71863A patent/IL71863A/xx not_active IP Right Cessation
- 1984-05-17 EP EP84105643A patent/EP0126449B1/en not_active Expired
- 1984-05-17 RU SU843741049A patent/RU2071471C1/ru active
- 1984-05-17 JP JP59097630A patent/JPS59219271A/ja active Granted
- 1984-05-17 ES ES532565A patent/ES532565A0/es active Granted
- 1984-05-17 IE IE1224/84A patent/IE57487B1/en not_active IP Right Cessation
- 1984-05-17 CA CA000454628A patent/CA1256874A/en not_active Expired
- 1984-05-17 DK DK248384A patent/DK168535B1/da not_active IP Right Cessation
- 1984-05-17 PL PL1984252856A patent/PL143558B1/pl unknown
- 1984-05-17 FI FI841989A patent/FI78479C/fi not_active IP Right Cessation
- 1984-05-17 DE DE8484105643T patent/DE3468215D1/de not_active Expired
- 1984-05-17 AU AU28346/84A patent/AU566489B2/en not_active Expired
1989
- 1989-11-16 HK HK919/89A patent/HK91989A/en not_active IP Right Cessation
1991
- 1991-11-12 RU SU915001933A patent/RU2083570C1/ru active
1992
- 1992-06-18 MX MX9203001A patent/MX9203001A/es unknown
1997
- 1997-05-05 BR BR1100474-6A patent/BR1100474A/pt active IP Right Grant

Also Published As

Publication number	Publication date
NO163618B (no)	1990-03-19
AU566489B2 (en)	1987-10-22
CA1256874A (en)	1989-07-04
ES8601947A1 (es)	1985-12-01
ES532565A0 (es)	1985-12-01
CS246080B2 (en)	1986-10-16
IE841224L (en)	1984-11-18
NZ208188A (en)	1987-10-30
RU2083570C1 (ru)	1997-07-10
NO841968L (no)	1984-11-19
DK248384D0 (da)	1984-05-17
JPH0469151B2 (cs)	1992-11-05
HU192404B (en)	1987-06-29
KR850002475A (ko)	1985-05-13
FI78479C (fi)	1989-08-10
KR890000020B1 (ko)	1989-03-06
PL252856A1 (en)	1985-11-19
IE57487B1 (en)	1993-02-10
NO163618C (no)	1990-06-27
HK91989A (en)	1989-11-24
PL142760B1 (en)	1987-11-30
FI841989A7 (fi)	1984-11-19
DK168535B1 (da)	1994-04-18
EP0126449A1 (en)	1984-11-28
PL247722A1 (en)	1985-08-13
BR1100474A (pt)	2000-03-14
IL71863A0 (en)	1984-09-30
JPS59219271A (ja)	1984-12-10
MX9203001A (es)	1992-07-01
PT78604B (en)	1986-07-15
AU2834684A (en)	1984-11-22
FI841989A0 (fi)	1984-05-17
FI78479B (fi)	1989-04-28
DE3468215D1 (en)	1988-02-04
PL143558B1 (en)	1988-02-29
HUT34177A (en)	1985-02-28
DK248384A (da)	1984-11-19
RU2071471C1 (ru)	1997-01-10
EP0126449B1 (en)	1987-12-23
US4567264A (en)	1986-01-28
PT78604A (en)	1984-06-01
ATE31533T1 (de)	1988-01-15
IL71863A (en)	1987-10-30
SG25086G (en)	1989-12-29
ZA843746B (en)	1986-01-29

Publication	Publication Date	Title
PH20016A (en)	1986-09-01	Cardioselective aryloxy-and arylthio-hydroxy-propylene piperazinyl acetamides which affect calcium entry
NO903851D0 (no)	1990-09-04	Fremgangsmaate for fremstilling av n-substituerte-4-pyrimidinaminer og -pyrimidindiaminer, og deres anvendelse som medikamenter.
DE69435220D1 (de)	2009-09-03	Das Natrium Salz des (-)-Enantiomer von Omeprazole
HUT45503A (en)	1988-07-28	Process for producing alpha-alkyl-(4-amino-3-quinolinyl)-methanols, 1-/4-(aralkyl-amino)-3-quinolinyl/-alkanones and pharmaceutics comprising these compounds as active ingredient
NO874834D0 (no)	1987-11-19	Fremgangsmaate for fremstilling av terapeutisk aktive tienopyridinoner.
GB2116964A (en)	1983-10-05	(1-(2-benzoxazolyl)hydrazinojalkyl nitrile derivatives
NZ528997A (en)	2004-12-24	Sulfonamides
ZA89389B (en)	1989-10-25	Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
TW349864B (en)	1999-01-11	Use of N-(pyridinyl)-1H-indol-a-amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
NO934741L (no)	1994-06-24	Fremgangsmåte for minimalisering og kontroll av ischemiske og reperfusjonsskade
ATE53385T1 (de)	1990-06-15	Sulfinyl- und sulfonylsubstituierte 3benzazepine.
NO915036D0 (no)	1991-12-19	Analogifremgangsmaate for fremstilling av terapeutisk virksomme 1,3-dioxolanderivater
DK347387D0 (da)	1987-07-06	Amidderivater
NO840732L (no)	1984-08-29	Analogifremgangsmaate for fremstilling av den terapeutisk aktive forbindelse n-(3-trifluormetylfenyl)-n`-propargylpiperazin
EA199700299A1 (ru)	1998-04-30	Азольные соединения с противогрибковой (антимикозной) активностью, применяемые для лечения людей и в ветеринарии